Phase II study on voriconazole for treatment of chinese patients with malignant hematological disorders and invasive aspergillosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2415-2418

  Zhang, Xue Zhong ^a   Huang, Xin En ^b   Xu, Yan Li ^a   Zhang, Xiu Qun ^a   Su, Ai ling ^a   Shen, Zheng Shan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Aspergillus; Hematological disorders; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROGNOSIS;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PYRIMIDINES; TRIAZOLES;

EID: 84872679439     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2415     Document Type: Article

References (36)

1. Baddley JW, Andes DR, Marr KA, et al (2012). Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol. 2012 Jun 11.
2. Egerer G, Reichert D, Pletz MW, et al (2012). Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry. Eur J Med Res, 17, 7.
3. Herbrecht R, Denning DW, Patterson TF, et al (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, 408-15.
4. Hilde VC, Sophie M, Marie-Paule D, et al (2008). Voriconazole treatment of invasive aspergillosis. Clin Drug Invest, 28, 509-21.
5. Hoenigl M, Strenger V, Buzina W, et al (2012). European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. published online on May 7, 2012 and accessed on Jun 2nd, 2012.
6. Horbrecht R, Letscher-Bru V, Oprea C, et al (2002). Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol, 20, 1898-906.
7. Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
8. Huang XE, Li CG, Li Y, et al (2011). European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. Asian Pac J Cancer Prev, 12, 2797-800.
9. Georgiadou SP, Kontoyiannis DP, et al (2012). Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis? J Infect. 2012 May 9.
10. Godet C, Elsendoorn A, Roblot F, et al (2012). Benefit of CT scanning for assessing pulmonary disease in the immunodepressed patient. Diagn Interv Imaging, 93, 425-30.
11. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, in press.
12. Hadrich I, Makni F, Neji S, et al (2012). Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol. 2012 May 15.
13. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
14. Kriengkauykiat J, Ito JI, Dadwal SS (2011). Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol, 3, 175-91.
15. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
16. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
17. Mengoli C, Cruciani M, Barnes RA, et al (2009). Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis, 9, 89-96.
18. Metzke B, Neubauer WC, Hieke S, et al (2012). Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol Drug Saf. published online on 2012 May 28. doi: 10.1002/pds.3278, and accessed on Jun 2nd, 2012.
19. Miller MA, DiNunzio J, Matteucci ME, et al (2012). Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm, 38, 557-70.
20. Misra R, Malik A, Singhal S (2011). Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species. Indian J Pathol Microbiol, 54, 112-6.
21. Nicolle MC, Bénet T, Thiebaut A, et al (2011). Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 96, 1685-91.
22. Ohba H, Miwa S, Shirai M, et al (2012). Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med, 106, 724-9.
23. Reinwald M, Spiess B, Heinz WJ, et al (2012). Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012 Jun 1. doi: 10.1111/j.1600-0609.2012.01806.x.
24. Sambatakou H, Dupont B, Lode H, et al (2006). Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med, 119, 527.e17-24.
25. Schwartz S, Reisman A, Troke PF (2011). The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection, 39, 201-10.
26. Springer J, Schloβnagel H, Heinz W, et al (2012). A novel extraction method combining plasma with whole blood fraction shows excellent sensitivity and reproducibility in patients at high risk for invasive aspergillosis. J Clin Microbiol. 2012 May 16.
27. Stefan S, Markus R, Patricia R, et al (2005). Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood, 106, 2641-5.
28. Stopiglia CD, Arechavala A, Carissimi M, et al (2012). Standardization and characterization of antigens for the diagnosis of aspergillosis. Can J Microbiol, 58, 455-62.
29. Tabarsi P, Soraghi A, Marjani M, et al (2012). Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant, 10, 278-81.
30. Wang ZY, Cai JP, Qiu LW, et al (2012). Development of monoclonal antibody-based galactomannoprotein antigen-capture ELISAs to detect Aspergillus fumigatus infection in the invasive aspergillosis rabbit models. Eur J Clin Microbiol Infect Dis. 2012 Jun 5.
31. White PL, Bretagne S, Klingspor L, et al (2010). Aspergillus PCR: one step closer to standardization. J Clin Microbiol, 48, 1231-40.
32. Wingard JR, Carter SL, Walsh TJ, et al (2010). Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 116, 5111-8.
33. Yan PW, Huang XE, Jiang Y, et al (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
34. Yuan X, Wang R, Bai CQ, et al(2012). Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials. Pharmazie, 67, 267-73.
35. Yu DS, Huang XE, Zhou JN (2012). A comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, in press.
36. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.